ProfessionalDiscontinued

Letters of Support from Experts re: Access to Psilocybin for Training Purposes

A collection of letters of support from healthcare professionals, researchers, and experts regarding legal access to psilocybin for healthcare professional training. The page explains the need for experiential training in psilocybin-assisted psychotherapy and the exemption process referenced by TheraPsil.

Provider

English

Details

5 years

Enrollment

Price on request
This course is currently marked as discontinued.

Course Overview

This course page presents supporting statements from clinicians and researchers about allowing healthcare professionals to access psilocybin for training purposes. The source material focuses on experiential training as part of preparing practitioners to facilitate psilocybin-assisted psychotherapy. It describes TheraPsil's training context, including the need for qualified healthcare professionals who can provide safe and effective care in this modality. The page also outlines the legal framework referenced in the source, including Section 56 exemptions and the Special Access Program. The content is aimed at healthcare professionals involved in psilocybin therapy training, as well as those interested in the policy and clinical rationale for experiential learning. The page includes individual letters of support from named experts.

Who is this for?

Healthcare professionals, therapists, researchers, and clinicians interested in psilocybin-assisted psychotherapy training and access.

Prerequisites

None stated on the source page.

About the Provider

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

View Therapsil profile

Course Details